Expert Interview
A Second Opinion: Looking at the new results from the Phase 3 CARTITUDE-4 study of CARVYKTI presented at ASH2024, as well as the Phase II iMMagin data on Anito-Cel from Gilead/Arcellx
Ticker(s): JNJ, GILD, ACLX, LEGNInstitution: Ohio State University
- Assistant Professor of Hematology at Ohio State University.
- Manages 100 patients with relapsed/refractory multiple myeloma.
- Research focuses on the development of novel anti-myeloma drugs through participation in clinical trials; clinical focus is on high risk patients and those with relapsed/refractory disease.
Describe your background and practice setting
Added By: ben_adminHow many patients with multiple myeloma do you manage?
Added By: ben_adminWhat are your thoughts on the potential of Carvykti and Anito-cel?
Added By: ben_adminWhere do you see CART therapies fitting into the future treatment algorithm of multiple myeloma?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
